Baird Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $26
Oppenheimer Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $27
Nurix Therapeutics Analyst Ratings
Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $27
Nurix Therapeutics Price Target Announced at $36.00/Share by Truist Securities
Nurix Therapeutics Analyst Ratings
Nurix Therapeutics (NRIX) Receives a Buy From Truist Financial
Truist Financial Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $36
Stifel Nicolaus Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
Nurix Therapeutics Analyst Ratings
Barclays Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)
Nurix Therapeutics (NRIX) Receives a Buy From Wells Fargo
Piper Sandler Remains a Buy on Nurix Therapeutics (NRIX)
RBC Lifts Price Target on Nurix Therapeutics to $27 From $26, Keeps Outperform, Speculative Risk
Nurix Therapeutics Analyst Ratings
Needham Maintains Buy on Nurix Therapeutics, Lowers Price Target to $29
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $26
Nurix Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Nurix Therapeutics, Raises Price Target to $31
Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target